Myositis ossificans progressiva, unspecified shoulder
ICD-10 M61.119 is a billable code used to indicate a diagnosis of myositis ossificans progressiva, unspecified shoulder.
Myositis ossificans progressiva (MOP) is a rare genetic disorder characterized by the abnormal formation of bone in muscles and connective tissues. This condition typically begins in early childhood and progresses over time, leading to significant muscle weakness and restricted mobility. In the case of unspecified shoulder involvement, patients may experience stiffness, pain, and decreased range of motion in the shoulder joint due to the ossification process. The condition is caused by mutations in the ACVR1 gene, which plays a crucial role in bone development and regulation. Diagnosis is often made through clinical evaluation, imaging studies, and family history. Management focuses on symptomatic relief, physical therapy, and avoiding trauma to affected areas to prevent exacerbation of ossification. Understanding the nuances of myositis ossificans progressiva is essential for accurate coding and appropriate patient care.
Detailed history of symptoms, family history, and results of imaging studies.
Patients presenting with progressive muscle stiffness and pain, particularly in the shoulder region.
Documentation should clearly outline the progression of symptoms and any interventions attempted.
Genetic testing results, family pedigree, and detailed clinical evaluation.
Patients with a family history of myositis ossificans or unexplained muscle ossification.
Accurate coding requires confirmation of genetic mutations associated with the condition.
Used for assessing functional limitations in patients with myositis ossificans progressiva.
Detailed evaluation of range of motion and functional capacity.
Rheumatology and physical therapy should coordinate documentation.
Myositis ossificans progressiva is a rare genetic disorder characterized by the abnormal formation of bone in muscles and connective tissues, leading to progressive stiffness and pain.
Diagnosis is typically made through clinical evaluation, imaging studies, and genetic testing to confirm mutations in the ACVR1 gene.
